Qiagen (NYSE:QGEN – Get Free Report) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 2.160- for the period, compared to the consensus estimate of 2.120. The company issued revenue guidance of $2.0 billion-, compared to the consensus revenue estimate of 2.160.
Qiagen Stock Down 0.2 %
QGEN traded down $0.09 on Friday, hitting $45.42. 847,455 shares of the company were exchanged, compared to its average volume of 1,245,056. Qiagen has a twelve month low of $34.74 and a twelve month high of $46.55. The company has a market cap of $10.36 billion, a price-to-earnings ratio of 30.46, a price-to-earnings-growth ratio of 3.19 and a beta of 0.40. The company has a current ratio of 1.77, a quick ratio of 1.45 and a debt-to-equity ratio of 0.27. The firm has a 50-day moving average price of $42.85 and a two-hundred day moving average price of $43.04.
Qiagen (NYSE:QGEN – Get Free Report) last issued its earnings results on Wednesday, July 31st. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.52 by $0.03. Qiagen had a net margin of 3.75% and a return on equity of 12.92%. The firm had revenue of $496.00 million during the quarter, compared to the consensus estimate of $495.45 million. During the same quarter in the previous year, the firm posted $0.53 earnings per share. The company’s revenue was down .2% compared to the same quarter last year. On average, equities analysts predict that Qiagen will post 2.15 earnings per share for the current year.
Wall Street Analyst Weigh In
Get Our Latest Stock Analysis on QGEN
Qiagen Company Profile
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
Read More
- Five stocks we like better than Qiagen
- Most Volatile Stocks, What Investors Need to Know
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- MarketBeat Week in Review – 8/5 – 8/9
- The 3 Best Fintech Stocks to Buy Now
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.